In a significant development for the Indian healthcare sector, the cardiac and anti-diabetes drugs market has expanded more than threefold over the past decade, according to recent data from market research firm Pharmarack. The anti-diabetes segment has seen remarkable growth, escalating from ₹5,000 crore in 2014